國立高雄大學圖資館 |

登入

回首頁

Lipoprotein(a)

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Lipoprotein(a)edited by Karam Kostner, Gerhard M. Kostner, Peter P. Toth.
其他作者:	Kostner, Karam.
出版者:	Cham :Springer International Publishing :2023.
面頁冊數:	xvii, 443 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Lipoprotein A.
電子資源:	https://doi.org/10.1007/978-3-031-24575-6
ISBN:	9783031245756$q(electronic bk.)

Lipoprotein(a)
Lipoprotein(a)[electronic resource] /edited by Karam Kostner, Gerhard M. Kostner, Peter P. Toth. - Cham :Springer International Publishing :2023. - xvii, 443 p. :ill. (some col.), digital ;24 cm. - Contemporary cardiology,2196-8977. - Contemporary cardiology..

60 years of Lp(a) research-From Ouchterlonys double diffusion to a significant risk factor for CHD -- Lp(a) structure and composition -- Genetics of Lipoprotein(a) -- Lp(a) metabolism -- Contemporary aspects of Lp(a) metabolism and therapies based on tracer kinetic methods -- Role of Proprotein Convertase Subtilisin Kexin type 9 in Lipoprotein(a) Metabolism -- The Role of Cell Surface Receptors in Lp(a) Metabolism -- Physiological Roles And Functions Of Lipoprotein(a) -- The role of Lp(a) in Atherosclerosis: An overview -- Role of macrophages in Lp(a) pathophysiology -- Thrombosis, Inflammation and Lipoprotein(a): Clinical Implications -- The role of the kidney in Lp(a) physiology and pathophysiology -- Lp(a) as a cardiovascular risk factor -- Lp(a) and aortic valve stenosis, stroke, and other non-coronary cardiovascular diseases -- Lp(a) in cardiovascular disease: Evidence from Large Epidemiological Studies -- Lipoprotein(A) And Immunity -- When to measure Lp(a) -- Measurement of Lipoprotein (a) in the Clinical Laboratory -- Standardization of analytical methods for the measurement of Lipoprotein(a): bridging past and future initiatives -- Establishing an SI-traceable Reference Measurement System for Lp(a), based on Quantitative Protein Mass Spectrometry and Molar Units -- Compounds that impact Lp(a) concentrations -- Antisense oligonucleotide therapy to treat elevated lipoprotein(a) -- Lipoprotein apheresis for reduction of Lipoprotein(a) -- Elevated Lp(a) - Why Should I Test For It, If I Cannot Treat It? A Patient's Perspective -- Burning unanswered questions Therapy.

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. This book offers an authoritative and comprehensive overview of Lipoprotein(a) It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies. Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

ISBN: 9783031245756$q(electronic bk.)

Standard No.: 10.1007/978-3-031-24575-6doiSubjects--Topical Terms:

947244
Lipoprotein A.

LC Class. No.: QP552.L5

Dewey Class. No.: 572.68

Lipoprotein(a)
LDR:03850nmm a2200337 a 4500 001 640499
003 DE-He213
005 20230303131416.0
006 m d
007 cr nn 008maaau
008 231025s2023 sz s 0 eng d
020 $a 9783031245756$q(electronic bk.)
020 $a 9783031245749$q(paper)
024 7 $a 10.1007/978-3-031-24575-6 $2 doi
035 $a 978-3-031-24575-6
040 $a GP $c GP
041 0 $a eng
050 4 $a QP552.L5
072 7 $a MJD $2 bicssc
072 7 $a MED010000 $2 bisacsh
072 7 $a MJD $2 thema
082 0 4 $a 572.68 $2 23
090 $a QP552.L5 $b L764 2023
245 0 0 $a Lipoprotein(a) $h [electronic resource] / $c edited by Karam Kostner, Gerhard M. Kostner, Peter P. Toth.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2023.
300 $a xvii, 443 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Contemporary cardiology, $x 2196-8977
505 0 $a 60 years of Lp(a) research-From Ouchterlonys double diffusion to a significant risk factor for CHD -- Lp(a) structure and composition -- Genetics of Lipoprotein(a) -- Lp(a) metabolism -- Contemporary aspects of Lp(a) metabolism and therapies based on tracer kinetic methods -- Role of Proprotein Convertase Subtilisin Kexin type 9 in Lipoprotein(a) Metabolism -- The Role of Cell Surface Receptors in Lp(a) Metabolism -- Physiological Roles And Functions Of Lipoprotein(a) -- The role of Lp(a) in Atherosclerosis: An overview -- Role of macrophages in Lp(a) pathophysiology -- Thrombosis, Inflammation and Lipoprotein(a): Clinical Implications -- The role of the kidney in Lp(a) physiology and pathophysiology -- Lp(a) as a cardiovascular risk factor -- Lp(a) and aortic valve stenosis, stroke, and other non-coronary cardiovascular diseases -- Lp(a) in cardiovascular disease: Evidence from Large Epidemiological Studies -- Lipoprotein(A) And Immunity -- When to measure Lp(a) -- Measurement of Lipoprotein (a) in the Clinical Laboratory -- Standardization of analytical methods for the measurement of Lipoprotein(a): bridging past and future initiatives -- Establishing an SI-traceable Reference Measurement System for Lp(a), based on Quantitative Protein Mass Spectrometry and Molar Units -- Compounds that impact Lp(a) concentrations -- Antisense oligonucleotide therapy to treat elevated lipoprotein(a) -- Lipoprotein apheresis for reduction of Lipoprotein(a) -- Elevated Lp(a) - Why Should I Test For It, If I Cannot Treat It? A Patient's Perspective -- Burning unanswered questions Therapy.
520 $a Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. This book offers an authoritative and comprehensive overview of Lipoprotein(a) It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies. Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.
650 0 $a Lipoprotein A. $3 947244
650 1 4 $a Cardiology. $3 273804
650 2 4 $a Internal Medicine. $3 273839
700 1 $a Kostner, Karam. $3 947242
700 1 $a Kostner, Gerhard M. $3 947243
700 1 $a Toth, Peter P. $3 489806
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Contemporary cardiology. $3 558937
856 4 0 $u https://doi.org/10.1007/978-3-031-24575-6
950 $a Medicine (SpringerNature-11650)